Table I.
General characterization of HAE patients with COVID-19 (n = 56)
| Clinical characteristics | HAE C1-INH (n = 44) | HAE nC1-INH (n = 12) | Total (n = 56) | P |
|---|---|---|---|---|
| Mean age, y (SD) | 42.07 ± 14.6 | 38.2 ± 13.3 | 41.25 ± 14.3 | |
| Age, y (n [%])∗ | ||||
| 10-19 | 1 (2.7%) | 1 (8.3%) | 2 (3.6%) | |
| 20-29 | 8 (18.1%) | 1 (8.3%) | 9 (16.1%) | |
| 30-39 | 11 (25%) | 5 (41.6%) | 16 (28.6%) | |
| 40-49 | 14 (31.8 %) | 2 (16.6%) | 16 (28.6%) | |
| 50-59 | 4 (9%) | 2 (16.6 %) | 6 (10.7%) | |
| 60-69 | 3 (6.8 %) | 1 (8.3%) | 4 (7.1%) | |
| >70 | 3 (6.8%) | 0 | 3 (5.3%) | |
| Sex, n (%) | ||||
| Male | 12 (27.3) | 0 | 12 (21.4) | .051† |
| Female | 32 (72.7) | 12 (100) | 44 (78.6) | |
| Prophylaxis, n (%) | ||||
| No | 29 (51.8%) | 9 (16%) | 38 (67.8) | .674† |
| Androgens | 6 (10.7 %) | 2 (3.5%) | 8 (14.2) | |
| Tranexamic acid | 2 (3.6 %) | 1 (1.8%) | 3 (5.4) | |
| pdC1-INH | 3 (5.4%) | 0 | 3 (5.4) | |
| Progestins with or without tranexamic acid | 4 (7.1%) | 0 | 4 (7.1) | |
| Attacks during COVID-19, n (%) | .529‡ | |||
| Yes | 20 (35.7) | 4 (7.1) | 24 (42.9) | |
| No | 24 (42.9) | 8 (14.3) | 32 (57.1) | |
| Attack treatment | ||||
| Icatibant | 6 | 2 | 8 | |
| pdC1-INH | 3 | 0 | 3 | |
| Icatibant + pdC1-INH | 0 | 1 | 1 | |
| Icatibant + FFP | 1 | 0 | 1 | |
| Icatibant + rhC1-INH | 1 | 0 | 1 | |
| FFP | 2 | 0 | 2 | |
| LMWH | 1 | 0 | 1 | |
| None | 6 (30%) | 1 (25%) | 7(29.2%) | |
| Comorbidities, n (%) | ||||
| None | 29 (51.8) | 9 (16.1) | 38 (67.8) | |
| Obesity | 6 (10.7) | 2 (3.6) | 8 (14.3) | |
| Diabetes mellitus | 2 (3.6) | 1 (1.8) | 3 (5.4) | |
| Arterial hypertension | 3 (5.4) | 0 | 3 (5.4) | |
| Others (neoplasia, autoimmunity) | 4 (7.1) | 0 | 4 (7.1) | |
| Period with symptomatology (median d [interquartile range]) | 10 (7-14) | 8.5 (3-15) | — | |
| Evolution, n (%) | ||||
| Recovered | 41 (73.2) | 12 (21.4) | 52 (92.8) | |
| Sequelae§ | 2 (3.6) | 0 | 2 (3.6) | |
| Deceased | 1 (1.8) | 0 | 1 (1.8) |
HAE C1-INH, hereditary angioedema with C1 inhibitor deficiency; HAE nC1-INH, hereditary angioedema with normal C1 inhibitor; pdC1-INH, plasma derived C1 inhibitor.
P = HAE-C1-INH vs HAE-nC1-INH.
∗
Percentage of patients in relation to whole population (HAE-C1-INH = 44; HAE-nC1-INH = 12).
†
χ2 test.
‡
Fisher test.
§
Sequelae was considered for patients maintaining respiratory symptoms for longer than 60 d after the onset of COVID-19 symptoms.